The ProRx FDA warning letter: what compounded GLP-1 patients need to understand

FDA inspectors examined the ProRx facility in Exton, Pennsylvania from September 9 to September 19, 2025. They found two categories of problems.

First: ProRx had compounded tirzepatide using bulk drug substance on multiple dates — even though tirzepatide was no longer on FDA's drug shortage list and was not on the 503B Bulks List. Under section 503B of the Federal Food, Drug, and Cosmetic Act, a drug can only be legally compounded by an outsourcing facility if it either appears on the 503B Bulks List or is on the current shortage list at the time of compounding, distribution, and dispensing. Tirzepatide met neither condition.

Second: FDA investigators documented serious sterility failures in the facility's aseptic manufacturing environment. A voluntary recall followed on October 15, 2025: Tirzepatide Injection Lot PRORX08062025-3 (27mg/3mL, multidose vials) and various Semaglutide Injection lots in multiple strengths — all recalled due to lack of sterility assurance.

The formal warning letter was issued April 7, 2026, after FDA reviewed ProRx's October 24, 2025 response to the Form FDA 483 (the inspection observations document) and found the corrective actions incomplete.

When a drug appears on FDA's shortage list, 503B outsourcing facilities can compound it even without the substance being separately listed on the 503B Bulks List. Tirzepatide entered the shortage list during supply constraints in 2023–2024. When FDA determined the shortage had resolved, that exemption ended.

Continuing to compound tirzepatide after the shortage exemption lapsed — without the substance being on the 503B Bulks List — means those drugs didn't qualify for the legal exemptions outsourcing facilities rely on. As a result, those products were treated as unapproved new drugs under FDA law.

For background on the broader 503B framework and the FDA's proposal to remove GLP-1s from the bulks list, see our explainer on what the 503B removal proposal means.

The FDA inspector documented multiple specific failures in ProRx's aseptic (sterile) manufacturing environment:

• Microbial contamination: Colony-forming unit (CFU) recoveries were found on ISO 5 operator gloves and settle plates in the sterile production area — and the company approved and distributed products manufactured during those contamination events.
• Blocking first air: Operators placed hands and forearms directly over open trays of stoppers intended to be sterile during critical production operations in the ISO 5 area, interrupting sterile airflow protection.
• No disinfection during transfers: Materials transferred from the ISO 7 cleanroom into the ISO 5 laminar airflow workstation were not surface-disinfected.
• Non-sterilized equipment: An operator used non-sterilized scissors inside the ISO 5 sterile production area during a drug filling operation. The scissors were routinely stored in the ISO 7 area and only wiped before use.
• Facility conditions: Floors in the ISO 7 buffer room showed significant visible sporadic discoloration.

These are not documentation deficiencies. They are failures in the basic practices that prevent contaminated injectable products from reaching patients.

If you received a product from ProRx during the affected period, the voluntary recall covers Tirzepatide Lot PRORX08062025-3 and multiple semaglutide lots. If you still have any of these products, contact your prescriber and pharmacist immediately.

More broadly, this case illustrates something important: FDA oversight of 503B outsourcing facilities is not the same as FDA approval of the products they make. Being FDA-registered as a 503B facility means a facility has elected to operate under heightened oversight requirements — not that its products have been individually tested and approved by FDA.

Warning letters signal that compliance has broken down. They do not guarantee prior products were contaminated — but the voluntary recall in this case indicates the company itself assessed sterility assurance as insufficient.

• The current operational status of ProRx aseptic compounding as of May 2026 — the warning letter states aseptic compounding was suspended pending cleanroom certification.
• Whether additional recalls of other lots may follow.
• The regulatory outcome for ProRx — warning letters can lead to injunctions or facility closure if corrective actions are not adequate.

• Is my compounded GLP-1 medication coming from an FDA-registered 503B outsourcing facility? Which one?
• When was that facility last inspected by the FDA? Has it received any warning letters?
• If I had a prescription filled by ProRx, are any of my lot numbers subject to the recall?
• What steps can I take to verify the quality of medications from compounding pharmacies?

The ProRx enforcement action is a specific case, not a blanket indictment of the entire compounding pharmacy sector. But it demonstrates real consequences: sterility failures in an injectable drug facility, a recall citing lack of sterility assurance, and a pattern of non-compliance that drew two FDA warning letters in 13 months.

If you have a prescription from a 503B outsourcing facility, it is reasonable to ask your prescriber and pharmacy which facility supplies your medication and whether that facility has a clean inspection history. This is not alarm — it is the kind of question that makes oversight work.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• FDA warning letter WL #723704 to ProRx LLC, April 7, 2026. fda.gov
• FDA warning letter WL #696742 to ProRx LLC, March 4, 2025. fda.gov
• Partnership for Safe Medicines, May 18, 2026. safemedicines.org